Stay updated on Pegcetacoplan in C3 Glomerulopathy: Clinical Trial

Sign up to get notified when there's something new on the Pegcetacoplan in C3 Glomerulopathy: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pegcetacoplan in C3 Glomerulopathy: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now shown on the page, replacing Revision: v3.3.3. This appears to be a routine site version update and does not modify the study details or user-facing content.
    Difference
    0.0%
    Check dated 2026-01-14T01:37:38.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    The Locations section was updated to add new study sites across the United States, Australia, Canada, Japan, and Brazil and to remove several previously listed sites.
    Difference
    1%
    Check dated 2025-12-23T17:13:26.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    A new Publications section was added showing the NEJM 2025 article on pegcetacoplan in C3G/IC-MPGN and a PubMed auto-fill note.
    Difference
    0.1%
    Check dated 2025-12-09T01:22:22.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    A minor maintenance update is shown: Revision v3.3.2 was added and Revision v3.2.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T20:57:53.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Removed the government funding lapse notice banner. The study details, eligibility criteria, and locations remain unchanged.
    Difference
    0.2%
    Check dated 2025-11-17T18:13:21.000Z thumbnail image
  8. Check
    79 days ago
    Change Detected
    Summary
    Results for NCT05067127 were posted on ClinicalTrials.gov (Results First Posted 2025-08-06). The posted results include primary and several secondary outcomes, such as changes in urine protein-to-creatinine ratio (uPCR) and estimated glomerular filtration rate (eGFR).
    Difference
    0.2%
    Check dated 2025-11-03T12:53:39.000Z thumbnail image

Stay in the know with updates to Pegcetacoplan in C3 Glomerulopathy: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pegcetacoplan in C3 Glomerulopathy: Clinical Trial page.